Failure is yet to be determined as if Missling is successful with a Full or reasonable CMA with the current trial data, I'm positive history will be kind.
I am unhappy that this company has such incredibly good therapeutic assets but they squander their opportunities to capitalize on them. SMH.
If they ran another ph3 our stock would be in the $3-$5 range from the crooks squeezing Dr. Missling at a time when he needs money. Ghe 130 million would not be enough and would being us dangerously low.
If Dr. Missling gets the ball across the goal line with EU approval he/we win!